Description
Products
3 productsBrand: Xdarzane. Darzalex biosimilar candidate (anti-CD38). Multiple myeloma. Preclinical.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Xdivane. Opdivo biosimilar candidate (PD-1 inhibitor). Skin, lung, renal, head and neck, bladder cancer. Clinical phase (registration-enabling study ongoing). Partner: INTAS.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Ximluci. Lucentis biosimilar (VEGF-A inhibitor). Wet AMD, diabetic macular edema, diabetic retinopathy, RVO. Sold in 20 European and 4 non-European markets with STADA.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21